U.S. drugmaker Eli Lilly said on Thursday it was suing six more entities including medical spas and wellness centers for selling products claiming to contain tirzepatide,...
-U.S. drugmaker Eli Lilly said on Thursday it was suing six more entities including medical spas and wellness centers for selling products claiming to contain tirzepatide, the active ingredient in its popular diabetes drug, Mounjaro.
In its six separate lawsuits filed in the courts of Ohio, Texas, Hawaii and the District of Columbia, Lilly has alleged that these entities are falsely claiming that their compounded versions of tirzepatide are approved by the FDA. Demand has been outpacing supply for GLP-1 drugs, which include Novo Nordisk's Wegovy and Lilly's Zepbound and Mounjaro. Some doses of Mounjaro and Zepbound are expected to be available in limited quantities through the second quarter, according to the FDA.
In May, the Indianapolis-based drugmaker entered into a settlement deal with Totality Medispa, which was required to make a monetary payment to Lilly and implement other corrective measures.
Weight Loss Clinical Guidelines Guidelines Drug Shortages Medication Shortages Hawaii Ohio Social Media Texas
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly warns about dangers of fake and counterfeit Mounjaro, ZepboundEli Lilly also filed lawsuits against compounding pharmacies and medical spas.
Read more »
Alabama Attorney General files lawsuits over electric vehicle mandatesAlabama is one of twenty-four states joining the fight against electric vehicle mandates imposed on truck owners and operators across the country.Alabama attorn
Read more »
Man convicted of murder, served 12 years based on blind witness' testimony, files lawsuitsA Chicago man convicted of murder based in part on testimony from a legally blind eyewitness is suing the city and the police department.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro. The drugmaker said Friday that it was more than doubling its investment in a site near its Indianapolis headquarters.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Read more »
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supplyDemand for the drugs Mounjaro and Zepbound has far outpaced supply over the last year, forcing Eli Lilly to invest heavily to scale up its manufacturing.
Read more »